Abstract
Although the infectious risks of blood transfusion are remarkably small, the current multi-layered approach of donor screening, testing and deferral is unlikely to have as much impact in the future as it has in the past. Pathogen inactivation (PI) technologies have all but eliminated the infectious risks of plasma-derived protein fractions and will potentially provide additional protection against both known and as-yet-unidentified agents. The treatment of blood components using PI technologies continues to evolve and the impact of PI on product quality and recipient safety remains paramount and is yet to be fully determined. The presentation will focus on the issues surrounding pathogen inactivation of blood components and how they contrast with those involved in plasma fraction manufacturing.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
